Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

NASDAQ:JANX - US47103J1051 - Common Stock

22.72 USD
-0.33 (-1.43%)
Last: 8/29/2025, 4:38:20 PM
22.72 USD
0 (0%)
After Hours: 8/29/2025, 4:38:20 PM
Fundamental Rating

4

Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 547 industry peers in the Biotechnology industry. While JANX has a great health rating, there are worries on its profitability. JANX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year JANX has reported negative net income.
JANX had a negative operating cash flow in the past year.
JANX had negative earnings in each of the past 5 years.
In the past 5 years JANX always reported negative operating cash flow.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

With an excellent Return On Assets value of -10.23%, JANX belongs to the best of the industry, outperforming 83.36% of the companies in the same industry.
The Return On Equity of JANX (-10.67%) is better than 88.30% of its industry peers.
Industry RankSector Rank
ROA -10.23%
ROE -10.67%
ROIC N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for JANX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
JANX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, JANX has more shares outstanding
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

JANX has an Altman-Z score of 20.21. This indicates that JANX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of JANX (20.21) is better than 92.87% of its industry peers.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.21
ROIC/WACCN/A
WACC9.68%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 47.03 indicates that JANX has no problem at all paying its short term obligations.
JANX's Current ratio of 47.03 is amongst the best of the industry. JANX outperforms 99.27% of its industry peers.
JANX has a Quick Ratio of 47.03. This indicates that JANX is financially healthy and has no problem in meeting its short term obligations.
JANX's Quick ratio of 47.03 is amongst the best of the industry. JANX outperforms 99.27% of its industry peers.
Industry RankSector Rank
Current Ratio 47.03
Quick Ratio 47.03
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

5

3. Growth

3.1 Past

The earnings per share for JANX have decreased strongly by -97.80% in the last year.
The Revenue for JANX has decreased by -97.10% in the past year. This is quite bad
Measured over the past years, JANX shows a very strong growth in Revenue. The Revenue has been growing by 42.75% on average per year.
EPS 1Y (TTM)-97.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, JANX will show a decrease in Earnings Per Share. The EPS will decrease by -0.27% on average per year.
The Revenue is expected to grow by 90.47% on average over the next years. This is a very strong growth
EPS Next Y-83.47%
EPS Next 2Y-53.43%
EPS Next 3Y-42%
EPS Next 5Y-0.27%
Revenue Next Year-91.79%
Revenue Next 2Y-24.63%
Revenue Next 3Y-17.42%
Revenue Next 5Y90.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

JANX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -42.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-53.43%
EPS Next 3Y-42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JANX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (8/29/2025, 4:38:20 PM)

After market: 22.72 0 (0%)

22.72

-0.33 (-1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners110.92%
Inst Owner Change-3.79%
Ins Owners1.47%
Ins Owner Change1.05%
Market Cap1.37B
Analysts84.76
Price Target86.45 (280.5%)
Short Float %16.01%
Short Ratio10.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5%
Min EPS beat(2)-15.55%
Max EPS beat(2)5.55%
EPS beat(4)2
Avg EPS beat(4)-10.02%
Min EPS beat(4)-52.65%
Max EPS beat(4)22.57%
EPS beat(8)6
Avg EPS beat(8)15.29%
EPS beat(12)10
Avg EPS beat(12)16.66%
EPS beat(16)11
Avg EPS beat(16)9.8%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-93.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)-73.78%
Revenue beat(8)4
Avg Revenue beat(8)142.73%
Revenue beat(12)8
Avg Revenue beat(12)145.86%
Revenue beat(16)12
Avg Revenue beat(16)189.67%
PT rev (1m)3.35%
PT rev (3m)0.57%
EPS NQ rev (1m)-16.75%
EPS NQ rev (3m)-8.77%
EPS NY rev (1m)-12.4%
EPS NY rev (3m)-15.12%
Revenue NQ rev (1m)499.99%
Revenue NQ rev (3m)220%
Revenue NY rev (1m)104.55%
Revenue NY rev (3m)-56.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3109.9
P/FCF N/A
P/OCF N/A
P/B 1.38
P/tB 1.38
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.01
BVpS16.48
TBVpS16.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.23%
ROE -10.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.76%
Cap/Sales 207.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 47.03
Quick Ratio 47.03
Altman-Z 20.21
F-Score2
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-97.8%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-83.47%
EPS Next 2Y-53.43%
EPS Next 3Y-42%
EPS Next 5Y-0.27%
Revenue 1Y (TTM)-97.1%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-91.79%
Revenue Next 2Y-24.63%
Revenue Next 3Y-17.42%
Revenue Next 5Y90.47%
EBIT growth 1Y-119.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.08%
EBIT Next 3Y-32.61%
EBIT Next 5Y-20.63%
FCF growth 1Y-1.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.14%
OCF growth 3YN/A
OCF growth 5YN/A